The Adoptive Cell Therapy (ACT) market was impacted by relapsed /refractory Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Acute Lymphoblastic Leukemia (ALL), Chronic lymphocytic leukemia (CLL) data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for YESCARTA® (axicabtagene ciloleucel), lisocabtagene maraleucel (JCAR017), KTE-X19, AMG 420, and LV20.19CAR T (bispecific CAR T).

Companies presenting data included: Amgen, Celgene/Juno, Novartis, Gilead/Kite, Pregene Biotech.

Get immediate access to this 65-slide report so you can make better decisions today and prepare for tomorrow.

Adoptive Cell Therapy Report ASCO 2019

American Society of Clinical Oncology

Chicago, IL
May 31 to Jun 4

Share: